Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.

ABSTRACT:

SUBMITTER: Mallory RM 

PROVIDER: S-EPMC9365313 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature